Infant use of meningitis vaccine approved in Australia

11 September 2017

UK pharma major GlaxoSmithKline (LSE: GSK) has announced that Menveo (meningococcal ACWY oligosaccharide conjugate vaccine) has received Therapeutics Goods Administration (TGA) approval for use in younger age groups in Australia.

Menveo, which was acquired by GSK as part of its 2014 deal to buy Swiss pharma giant Novartis' (NOVN: VX) vaccines unit, is now approved for active immunization of infants from two months of age and children to prevent invasive disease caused by Neisseria meningitidis serogroups A, C, W135 and Y.

"The TGA decision is welcome news for parents who want to vaccinate their young infants against a broad range of meningococcal strains"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK